Floatz logo

cd19+cd22 car-t

Childhood Acute Lymphoblastic Leukemia

Hebei Senlang Biotechnology Inc., Ltd.Cell therapyEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Childhood Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Daunorubicin
Children's Mercy Hospital Kansas City
Phase 3BB
Idarubicine
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BB
Revumenib
Children's Oncology Group
Phase 1CC
Ari-0001
Hebei Senlang Biotechnology Inc., Ltd.
Early Phase 1C
cd22 car-t
Hebei Senlang Biotechnology Inc., Ltd.
Early Phase 1C
Peg-L-Asparaginase
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
N/AD

Same molecule, other indications

cd19+cd22 car-t is also rated in:

acute lymphoblastic leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
CCC
Indicative ·
51 / 100
View asset →
Refractory Indolent Adult Non-Hodgkin LymphomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →